Cargando…

Effect of pemafibrate (K-877), a novel selective peroxisome proliferator-activated receptor α modular (SPPARMα), in atherosclerosis model using low density lipoprotein receptor knock-out swine with balloon injury

BACKGROUND: Peroxisome proliferator-activated receptor α (PPARα) is a nuclear receptor that has key roles of lipid metabolism and inflammation. The PPARα may affects the initiation and progression of atherosclerosis by reducing inflammatory responses. Pemafibrate (K-877) is a novel selective PPARα m...

Descripción completa

Detalles Bibliográficos
Autores principales:	Konishi, Hirokazu, Miyauchi, Katsumi, Onishi, Akira, Suzuki, Shunichi, Fuchimoto, Daiichiro, Shitara, Jun, Endo, Hirohisa, Wada, Hideki, Doi, Shinichiro, Naito, Ryo, Ogita, Manabu, Dohi, Tomotaka, Kasai, Takatoshi, Daida, Hiroyuki
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2020
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7671509/ https://www.ncbi.nlm.nih.gov/pubmed/33201888 http://dx.doi.org/10.1371/journal.pone.0241195

Ejemplares similares

A Novel Selective PPARα Modulator (SPPARMα), K-877 (Pemafibrate), Attenuates Postprandial Hypertriglyceridemia in Mice
por: Sairyo, Masami, et al.
Publicado: (2018)

Erratum:A Novel Selective PPARα Modulator (SPPARMα), K-877 (Pemafibrate), Attenuates Postprandial Hypertriglyceridemia in Mice
por: Sairyo, Masami, et al.
Publicado: (2018)

Development of Accelerated Coronary Atherosclerosis Model Using Low Density Lipoprotein Receptor Knock-Out Swine with Balloon Injury
por: Ogita, Manabu, et al.
Publicado: (2016)

Gene Expression Profiles Induced by a Novel Selective Peroxisome Proliferator-Activated Receptor α Modulator (SPPARMα) Pemafibrate
por: Sasaki, Yusuke, et al.
Publicado: (2019)

Selective Peroxisome Proliferator-Activated Receptor Alpha Modulators (SPPARMα) in the Metabolic Syndrome: Is Pemafibrate Light at the End of the Tunnel?
por: Fruchart, Jean-Charles, et al.
Publicado: (2021)

Effect of fenofibrate and selective PPARα modulator (SPPARMα), pemafibrate on KATP channel activity and insulin secretion
por: Kitamura, Shigeki, et al.
Publicado: (2023)

Long-Term Efficacy and Safety of Pemafibrate, a Novel Selective Peroxisome Proliferator-Activated Receptor-α Modulator (SPPARMα), in Dyslipidemic Patients with Renal Impairment
por: Yokote, Koutaro, et al.
Publicado: (2019)

Differing effects of beta-blockers on long-term clinical outcomes following percutaneous coronary intervention between patients with mid-range and reduced left ventricular ejection fraction
por: Shitara, Jun, et al.
Publicado: (2021)

Effects of a Novel Selective Peroxisome Proliferator-Activated Receptor α Modulator K-877 (Pemafibrate) on Postprandial hyperlipidemia
por: Fujioka, Yoshio
Publicado: (2018)

Clinically Relevant Dose of Pemafibrate, a Novel Selective Peroxisome Proliferator-Activated Receptor α Modulator (SPPARMα), Lowers Serum Triglyceride Levels by Targeting Hepatic PPARα in Mice
por: Zhang, Zhe, et al.
Publicado: (2022)

Randomised clinical trial: Pemafibrate, a novel selective peroxisome proliferator‐activated receptor α modulator (SPPARMα), versus placebo in patients with non‐alcoholic fatty liver disease
por: Nakajima, Atsushi, et al.
Publicado: (2021)

Temporal Trends in Clinical Outcomes Following Percutaneous Coronary Intervention in Patients with Renal Insufficiency
por: Naito, Ryo, et al.
Publicado: (2016)

Efficacy and Safety of Pemafibrate, a Novel Selective Peroxisome Proliferator-Activated Receptor α Modulator (SPPARMα): Pooled Analysis of Phase 2 and 3 Studies in Dyslipidemic Patients with or without Statin Combination
por: Yamashita, Shizuya, et al.
Publicado: (2019)

Selective peroxisome proliferator-activated receptorα modulators (SPPARMα): The next generation of peroxisome proliferator-activated receptor α-agonists
por: Fruchart, Jean-Charles
Publicado: (2013)

Real-world Profile of a Selective Peroxisome Proliferator-activated Receptor α Modulator (SPPARMα) in Japanese Patients with Renal Impairment and Dyslipidemia
por: Komatsu, Toshinori, et al.
Publicado: (2021)

Increased risk of cardiovascular mortality by strict glycemic control (pre-procedural HbA1c < 6.5%) in Japanese medically-treated diabetic patients following percutaneous coronary intervention: a 10-year follow-up study
por: Funamizu, Takehiro, et al.
Publicado: (2020)

Clinical Outcomes in Diabetic Patients Who Underwent Percutaneous Coronary Intervention during the Plain Old Balloon Angioplasty (POBA)-, Bare Metal Stents (BMS)- and Drug-eluting Stents (DES)-eras from 1984 to 2010
por: Naito, Ryo, et al.
Publicado: (2017)

Pemafibrate (K-877), a novel selective peroxisome proliferator-activated receptor alpha modulator for management of atherogenic dyslipidaemia
por: Fruchart, Jean-Charles
Publicado: (2017)

Impact of Lipoprotein (a) on Long-Term Outcomes in Patients with Coronary Artery Disease Treated with Statin After a First Percutaneous Coronary Intervention
por: Suwa, Satoru, et al.
Publicado: (2017)

Comparing mortality between coronary artery bypass grafting and percutaneous coronary intervention with drug-eluting stents in elderly with diabetes and multivessel coronary disease
por: Naito, Ryo, et al.
Publicado: (2015)

The Goal of Achieving Atherosclerotic Plaque Regression with Lipid-Lowering Therapy: Insights from IVUS Trials
por: Daida, Hiroyuki, et al.
Publicado: (2019)

The Peroxisome Proliferator-Activated Receptor α (PPARα) Agonist Pemafibrate Protects against Diet-Induced Obesity in Mice
por: Araki, Masaya, et al.
Publicado: (2018)

Culprit Plaque Characteristics in Patients With Sleep‐Disordered Breathing Undergoing Percutaneous Coronary Intervention: An Intravascular Ultrasound Study
por: Wada, Hideki, et al.
Publicado: (2018)

Selective Peroxisome Proliferator–Activated Receptor Alpha Modulators (SPPARMα): New Opportunities to Reduce Residual Cardiovascular Risk in Chronic Kidney Disease?
por: Fruchart, Jean-Charles, et al.
Publicado: (2020)

A Prognostic Merit of Statins in Patients with Chronic Hemodialysis after Percutaneous Coronary Intervention—A 10-Year Follow-Up Study
por: Funamizu, Takehiro, et al.
Publicado: (2022)

Impact of serum 1,5-anhydro-d-glucitol level on the prediction of severe coronary artery calcification: an intravascular ultrasound study
por: Wada, Hideki, et al.
Publicado: (2019)

Selective peroxisome proliferator‐activated receptor‐α modulator K‐877 efficiently activates the peroxisome proliferator‐activated receptor‐α pathway and improves lipid metabolism in mice
por: Takei, Kenta, et al.
Publicado: (2017)

Dipeptidyl peptidase-4 inhibitors reduced long-term cardiovascular risk in diabetic patients after percutaneous coronary intervention via insulin-like growth factor-1 axis
por: Chikata, Yuichi, et al.
Publicado: (2022)

Low apolipoprotein A1 was associated with increased risk of cancer mortality in patients following percutaneous coronary intervention: A 10‐year follow‐up study
por: Nishiyama, Hiroki, et al.
Publicado: (2022)

Marked effects of novel selective peroxisome proliferator-activated receptor α modulator, pemafibrate in severe hypertriglyceridemia: preliminary report
por: Iitake, Chie, et al.
Publicado: (2020)

Impact of Prior Stroke on Long-Term Outcomes in Patients With Acute Coronary Syndrome
por: Takeuchi, Mitsuhiro, et al.
Publicado: (2021)

Highly Selective PPARα (Peroxisome Proliferator‐Activated Receptor α) Agonist Pemafibrate Inhibits Stent Inflammation and Restenosis Assessed by Multimodality Molecular‐Microstructural Imaging
por: Iwata, Hiroshi, et al.
Publicado: (2021)

Pemafibrate, a potent selective peroxisome proliferator-activated receptor α modulator, a promising novel treatment for ischemic retinopathy?
por: Lee, Deokho, et al.
Publicado: (2022)

Validation of telemedicine-based self-assessment of vital signs for patients with COVID-19: A pilot study
por: Kagiyama, Nobuyuki, et al.
Publicado: (2021)

Clinical indicators and coronary angiographic features of expansive arterial remodelling in patients with abdominal aortic aneurysms
por: Endo, Hirohisa, et al.
Publicado: (2019)

Effects of a Novel Selective Peroxisome Proliferator-Activated Receptor α Modulator, Pemafibrate, on Metabolic Parameters: A Retrospective Longitudinal Study
por: Yanai, Hidekatsu, et al.
Publicado: (2022)

Clinical features and predictors of outcome in patients with acute myocardial infarction complicated by out-of-hospital cardiac arrest
por: Sonoda, Taketo, et al.
Publicado: (2022)

Combination therapy with pemafibrate (K-877) and pitavastatin improves vascular endothelial dysfunction in dahl/salt-sensitive rats fed a high-salt and high-fat diet
por: Yoshida, Masatoki, et al.
Publicado: (2020)

Impact of simple equation for estimating appendicular skeletal muscle mass in patients with stable coronary artery disease undergoing percutaneous coronary intervention()
por: Nishio, Ryota, et al.
Publicado: (2022)

Successful Rotational Atherectomy for an Angulated Calcified Lesion in an Anomalous Right Coronary Artery Using the “Mother-and-Child” Technique
por: Ogita, Manabu, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_2eoltuckvsnokcbo3rd7oagv77